Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biota Of Australia Reaps Large Profits From Relenza Antiviral Royalties

This article was originally published in PharmAsia News

Executive Summary

Australia's Biota, the biotech that came up with the Relenza (zanamivir) antiviral marketed globally by U.K.-based GlaxoSmithKline, saw a doubling in royalties the past year. The near future looks even brighter for Biota, which reaped just over U.S.$31.5 million in profits, based primarily on the Relenza royalties. GSK plans by the end of the year to triple production of the drug as a major treatment for the widely expected H1N1 flu pandemic, so Biota anticipates a continuation of large royalties. (Click here for more

You may also be interested in...



‘Astonishing Results’ Or ‘Outrageous’ Claims? Peter Thomas Roth Fighting Bicoastal Class Actions

Plaintiffs against the prestige, “clinical” skin-care company are targeting anti-aging claims on its Rose Stem Cell Bio-Repair line and statements about hyaluronic acid’s ultra-moisturizing capabilities, used to market its Water Drench range. PTR faces false advertising class actions in California and New York federal courts, and the former case appears to be headed for trial.

Flagship, ARCH Close VC Funds Totaling $2.56bn

Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.

LifeSignals Plans To Market Biosensor Patch To Help Consumer Identify COVID-19 Symptoms

LifeSignals plans to soon launch a biosensor patch to consumers to help them monitor for potential symptoms of COVID-19. 

UsernamePublicRestriction

Register

SC072537

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel